These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 29409610

  • 21. Current status of immune checkpoint inhibition in early-stage NSCLC.
    Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D.
    Ann Oncol; 2019 Aug 01; 30(8):1244-1253. PubMed ID: 31143921
    [Abstract] [Full Text] [Related]

  • 22. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E, Cubitt A, Ballard E, Teng MWL, Dougall WC, Smyth MJ, Godbolt D, Naidoo R, Goldrick A, Hughes BGM.
    Trials; 2019 Dec 19; 20(1):753. PubMed ID: 31856909
    [Abstract] [Full Text] [Related]

  • 23. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
    Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R.
    Eur J Cancer; 2019 Jan 19; 106():144-159. PubMed ID: 30528799
    [Abstract] [Full Text] [Related]

  • 24. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.
    Rebuzzi SE, Leonetti A, Tiseo M, Facchinetti F.
    Immunotherapy; 2019 Aug 19; 11(12):993-1003. PubMed ID: 31319742
    [No Abstract] [Full Text] [Related]

  • 25. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.
    J Clin Oncol; 2018 Jul 01; 36(19):1905-1912. PubMed ID: 29746230
    [Abstract] [Full Text] [Related]

  • 26. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J, Gu J.
    Future Oncol; 2019 May 01; 15(14):1667-1678. PubMed ID: 31041879
    [Abstract] [Full Text] [Related]

  • 27. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM, Vella ET, Ung YC.
    Clin Lung Cancer; 2017 Sep 01; 18(5):444-459.e1. PubMed ID: 28416123
    [Abstract] [Full Text] [Related]

  • 28. The benefits of immunotherapy combinations.
    Schmidt C.
    Nature; 2017 Dec 21; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract] [Full Text] [Related]

  • 29. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH, Kim HS, Kim BJ.
    Oncotarget; 2017 Jul 18; 8(29):48248-48252. PubMed ID: 28525386
    [Abstract] [Full Text] [Related]

  • 30. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.
    Lichtenstein MRL, Nipp RD, Muzikansky A, Goodwin K, Anderson D, Newcomb RA, Gainor JF.
    J Thorac Oncol; 2019 Mar 18; 14(3):547-552. PubMed ID: 30476576
    [Abstract] [Full Text] [Related]

  • 31. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    Li W, Yu H.
    J Cancer Res Clin Oncol; 2020 Jan 18; 146(1):137-152. PubMed ID: 31813004
    [Abstract] [Full Text] [Related]

  • 32. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.
    Rev Pneumol Clin; 2018 Oct 18; 74(5):339-350. PubMed ID: 30337201
    [Abstract] [Full Text] [Related]

  • 33. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Check JH, Check D, Poretta T.
    Anticancer Res; 2019 Apr 18; 39(4):1923-1926. PubMed ID: 30952734
    [Abstract] [Full Text] [Related]

  • 34. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.
    J Thorac Oncol; 2019 Jul 18; 14(7):1244-1254. PubMed ID: 30780002
    [Abstract] [Full Text] [Related]

  • 35. Targeting immune checkpoints in non small cell lung cancer.
    Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G.
    Curr Opin Pharmacol; 2018 Jun 18; 40():46-50. PubMed ID: 29525401
    [Abstract] [Full Text] [Related]

  • 36. Immunotherapy in Advanced Lung Cancer.
    Huang J, Reckamp KL.
    Oncology (Williston Park); 2020 Jul 15; 34(7):272-279. PubMed ID: 32674216
    [Abstract] [Full Text] [Related]

  • 37. First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
    Landre T, Des Guetz G, Chouahnia K, Taleb C, Vergnenègre A, Chouaïd C.
    J Cancer Res Clin Oncol; 2020 Feb 15; 146(2):441-448. PubMed ID: 31686247
    [Abstract] [Full Text] [Related]

  • 38. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Zhu Z, Chen P, Yan Z.
    Thorac Cancer; 2018 Aug 15; 9(8):901-903. PubMed ID: 29932513
    [No Abstract] [Full Text] [Related]

  • 39. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L, Planchard D.
    Future Oncol; 2018 Feb 15; 14(3):205-222. PubMed ID: 29140105
    [Abstract] [Full Text] [Related]

  • 40. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R, Chow LQ.
    Future Oncol; 2018 Feb 15; 14(3):191-194. PubMed ID: 29334785
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.